BioSpace News Archive

Moderna, Inc today announced significant advances across its portfolio of mRNA pipeline programs being presented at the Company’s fifth annual R&D Day today.

Olema Pharmaceuticals, Inc. today announced a poster presentation of new preclinical data on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers, at the 1st JCA-AACR Precision Cancer Medicine International Conference being held virtually from September 10-12, 2021 (U.S.) and September 11-12 (Japan).

Vera Therapeutics, Inc announced today that it is scheduled to host a key opinion leader (KOL) webinar on IgA Nephropathy (IgAN or Berger’s Disease) at 12:00 p.m. ET on Monday, September 20, 2021.

Rapid Micro Biosystems, Inc. today announced that it is set to join the Russell 2000®, Russell 3000® and Russell Microcap® indexes, effective after the U.S. market opens on September 20, 2021

Diffusion Pharmaceuticals Inc. today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders.

Enveric Biosciences today announced that Dr. Joseph Tucker, MagicMed Industries’ (“MagicMed”) Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and Virtual Gravitas Health Reimagined Investor Day.

- Biohaven presenting 17 abstracts, including three late-breaking abstracts and four oral presentations, highlighting the efficacy and safety of Nurtec ODT as both an acute and preventive treatment of migraine

Invacare Corporation (NYSE:IVC) (“Invacare” or the “company”) will participate today in the 19th Annual Morgan Stanley Global Healthcare Conference with management available for 1x1 meetings with interested investors.

Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced that it has completed enrollment for its Phase 2a trial evaluating MET642, an optimized farnesoid X receptor agonist, in patients with non-alcoholic steatohepatitis.